GLP-1 Sales Surge
Sales of diabetes and weight-loss GLP-1 products jumped 25.5% year-over-year to $2.3 billion in the quarter, a key driver of U.S. Healthcare Solutions growth.
Cencora, Inc. is expected to release its Q3 2026 10-Q filing on November 3, 2026, after market close. Last quarter: Cencora's Q3 FY2026 results highlighted robust topline and bottom-line growth driven by the OneOncology acquisition and GLP-1 sales, yet rising costs and debt warrant attention.
EPS Estimate
$4.66
Revenue Estimate
$89.27B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the COR page.
Drawn from management commentary in the Q2 2026 10-Q:
Sales of diabetes and weight-loss GLP-1 products jumped 25.5% year-over-year to $2.3 billion in the quarter, a key driver of U.S. Healthcare Solutions growth.
The February 2026 acquisition of OneOncology significantly increased gross profit and operating income, but also drove a 27.5% rise in distribution, selling, and administrative expenses.
Dismissal of opioid litigation led to a $102 million reduction in opioid liability, resulting in a net credit in litigation and opioid-related expenses for the quarter.
Revenue
$84.75B
+5.07% YoY
EPS (Diluted)
$3.94
+11.93% YoY
Gross Margin
4.3%
+0.7 pts YoY
Operating Income
$1.12B
+29.11% YoY
Add COR to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.